SLC5A2 and hypertensive disorder: Therefore, the combined use of these agents may provide complementary renal haemodynamic protective actions (afferent vasoconstriction via SGLT2 inhibition and efferent vasodilation via finerenone) to optimally and efficiently attenuate intraglomerular hypertension.